Skip to main content

Advertisement

SpringerLink
Log in

Genetic variation in thrombin-activatable fibrinolysis inhibitor is associated with the risk of diabetic nephropathy

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Diabetic nephropathy is a kidney disease or damage that results as a complication of diabetes, especially Type 2 diabetes, while albuminuria is an early marker for diabetic nephropathy as it can predict cardiovascular events and mortality in diabetic patients. A potent inhibitor of fibrinolysis, the thrombin-activatable fibrinolysis inhibitor (TAFI) has been isolated and characterized from human plasma. We investigated the associations of the activity-related variants in the TAFI coding gene (505A/G, 1040C/T) with the risk of diabetic nephropathy by examining 297 samples including 140 health controls and 157 confirmed diabetic nephropathy patients. Diabetic nephropathy grades were further categorized by the urine albumin excretion (UAE)-to-creatinine ratios (ACR). We found little difference that was statistically significant in terms of 505A/G among patients and controls. While at 1040C/T, the detected frequency for the T allele in the group of diabetic nephropathy patients was significantly smaller than that of the control group (15.6% vs 25.7%, respectively; p<0.05). This was due to the relative decrease of T/T homozygotes in the patients (p<0.05, 95% odds ratio 0.28, confidence interval 0.11–0.70). Surprisingly, the difference was only observed with initial diabetic nephropathy stages. This study clearly indicates that, at 1040C/T, the frequency for the T allele is strongly associated with increased risk for diabetic nephropathy in a subset of the general population, implying that the T allele confers protection against the onset of diabetic nephropathy only in homozygosity and may function as a recessive trait.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Giacconi R, Bonfigli AR, Testa R, et al. +647 A/C and +1245 MT1A polymorphisms in the susceptibility of diabetes mellitus and cardiovascular complications. Mol Genet Metab 2008, 94: 98–104.

    Article  PubMed  CAS  Google Scholar 

  2. Zhang D, Freedman BI, Flekac M, et al. Evaluation of genetic association and expression reduction of TRPC1 in the development of diabetic nephropathy. Am J Nephrol 2009, 29: 244–51.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  3. Erem C, Hacihasanoglu A, Celik S, et al. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Med Princ Pract 2005, 14: 22–30.

    Article  PubMed  Google Scholar 

  4. Lapolla A, Piarulli F, Sartore G, et al. Peripheral artery disease in type 2 diabetes: the role of fibrinolysis. Thromb Haemost 2003, 89: 91–6.

    PubMed  CAS  Google Scholar 

  5. Maeda S, Osawa N, Hayashi T, Tsukada S, Kobayashi M, Kikkawa R. Genetic variations associated with diabetic nephropathy and type II diabetes in a Japanese population. Kidney Int Suppl 2007, 106: 43–8.

    Article  CAS  Google Scholar 

  6. Yano Y, Kitagawa N, Gabazza EC, et al. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab 2003, 88: 736–41.

    Article  PubMed  CAS  Google Scholar 

  7. Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003, 1: 1566–74.

    Article  PubMed  CAS  Google Scholar 

  8. Foley JH, Kim P, Nesheim ME. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis. J Biol Chem 2008, 283: 8863–7.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  9. Boffa MB, Maret D, Hamill JD, et al. Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis. Blood 2008, 111: 183–9.

    Article  PubMed  CAS  Google Scholar 

  10. Martini CH, Brandts A, de Bruijne EL, et al. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 2006, 134: 92–4.

    Article  PubMed  CAS  Google Scholar 

  11. Frère C, Tregouet DA, Morange PE, et al. Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. Blood 2006, 108: 1562–8.

    Article  PubMed  CAS  Google Scholar 

  12. Franco RF, Fagundes MG, Meijers JC, et al. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001, 86: 510–7.

    PubMed  CAS  Google Scholar 

  13. Henry M, Aubert H, Morange PE, et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001, 97: 2053–8.

    Article  PubMed  CAS  Google Scholar 

  14. Takada Y, Urano T, Watanabe I, Taminato A, Yoshimi T, Takada A. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res 1993, 71: 405–15.

    Article  PubMed  CAS  Google Scholar 

  15. Brosius FC 3rd. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord 2008, 9: 245–54.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  16. Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol 2002, 13: 1034–9.

    PubMed  CAS  Google Scholar 

  17. Knight EL, Kramer HM, Curhan GC. High-normal blood pressure and microalbuminuria. Am J Kidney Dis 2003, 41: 588–95.

    Article  PubMed  Google Scholar 

  18. Fuller JH, Keen H, Jarrett RJ, et al. Haemostatic variables associated with diabetes and its complications. Br Med J 1979, 2: 964–6.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  19. Bhattacharya S, Mandal SK, Bandyopadhyay R, Chakrabarti S, Basu AK, Pal S. A study on nephropathy in type 2 diabetes mellitus: histology and its correlation with clinical and biochemical parameters. J Indian Med Assoc 2007, 105: 594–6.

    Google Scholar 

  20. Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 2007, 40: 431–42.

    Article  PubMed  CAS  Google Scholar 

  21. Morange PE, Tregouet DA, Frere C, et al; Prime Study Group. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. J Thromb Haemost 2005, 3: 1503–10.

    Article  PubMed  CAS  Google Scholar 

  22. Hori Y, Gabazza EC, Yano Y, et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002, 87: 660–5.

    Article  PubMed  CAS  Google Scholar 

  23. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and IIe-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002, 277: 1021–30.

    Article  PubMed  CAS  Google Scholar 

  24. Brouwers GJ, Vos HL, Leebeek FW, et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001, 98: 1992–3.

    Article  PubMed  CAS  Google Scholar 

  25. Ceresa E, Van de Borne K, Peeters M, Lijnen HR, Declerck PJ, Gils A. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant. J Biol Chem 2006, 281: 15878–83.

    Article  PubMed  CAS  Google Scholar 

  26. Guimarães AH, Laurens N, Weijers EM, Koolwijk P, van Hinsbergh VW, Rijken DC. TAFI and pancreatic carboxypeptidase B modulate in vitro capillary tube formation by human microvascular endothelial cells. Arterioscler Thromb Vasc Biol 2007, 27: 2157–62.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, the Second Hospital, Shandong University, 247#, Beiyuan Street, Jinan, 250033, P.R. China

    C.-W. Xu MD, PhD & Z.-J. Wang

  2. Department of Laboratory Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Shandong, China

    X.-B. Wu & B.-C. Zhang

  3. Medical Research & Laboratory Diagnostic Center, Jinan Central Hospital Affiliated to Shandong University, Jinan, China

    X.-L. Ma, Y.-S. Wang & J.-J. Zhao

  4. Department of Emergency Medicine, The First Affiliated Hospital, Zhongshan University, Guangzhou, China

    J. Chen

Authors
  1. C.-W. Xu MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X.-B. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X.-L. Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y.-S. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B.-C. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J.-J. Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Z.-J. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C.-W. Xu MD, PhD.

Additional information

C.-W. Xu and X.-B. Wu contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, CW., Wu, XB., Ma, XL. et al. Genetic variation in thrombin-activatable fibrinolysis inhibitor is associated with the risk of diabetic nephropathy. J Endocrinol Invest 35, 620–624 (2012). https://doi.org/10.1007/BF03345800

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345800

Key-words

Search

Navigation